CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis

Molecular Medicine Reports

Volumn 7, Issue 1, 2013, Pages 237-241

  Wu, Jilong ^a   Zhou, Miaoni ^a   Wan, Yinsheng ^b   Xu, Aie ^a  

^a THE THIRD PEOPLE S HOSPITAL OF HANGZHOU   (China)

^b PROVIDENCE COLLEGE   (United States)

Author keywords

CD8+ T cells; Cytokine; Melanocytes; Vitiligo

Indexed keywords

CD137 ANTIGEN; CD69 ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 6;

APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL INFILTRATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; CYTOTOXICITY; DEPIGMENTATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOCYTE; PROTEIN EXPRESSION; SKIN BIOPSY; VITILIGO;

APOPTOSIS; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CYTOKINES; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MELANOCYTES; PRIMARY CELL CULTURE; VITILIGO;

EID: 84873867929     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1117     Document Type: Article

References (36)

1. Yee C, Thompson JA, Roche P, et al: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637-44, 2000.
2. Kemp EH, Waterman EA, Hawes BE, et al: The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 109: 923-930, 2002.
3. Palermo B, Campanelli R, Garbelli S, et al: Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117: 326-332, 2001.
4. Glassman SJ: Vitiligo, reactive oxygen species and T-cells (Review). Clin Sci (Lond) 120: 99-120, 2011
5. Le Poole IC and Luiten RM: Autoimmune etiology of generalized vitiligo (Review). Curr Dir Autoimmun 10: 227-243, 2008.
6. Le Poole IC, ElMasri WM, Denman CJ, et al: Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother 57: 789-797, 2008
7. Ongenae K, Van Geel N and Naeyaert JM: Evidence for an autoimmune pathogenesis of vitiligo (Review). Pigment Cell Res 16: 90-100, 2003.
8. Badri AM, Todd PM, Garioch JJ, et al: An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 170: 149-155, 1993.
9. + T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83: 683-695, 2003.
10. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, et al: Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res 16: 254-260, 2003.
11. van den Wijngaard RM, Aten J, Scheepmaker A, et al: Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 143: 573-581, 2000.
12. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al: Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 80: 1299-1309, 2000.
13. Bos JD, Zonneveld I, Das PK, et al: The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 88: 569-573, 1987.
14. Gross AJ, Hunt HH, Cantor AB and Clark BC: Sample size determination in clinical trials with an emphasis on exponentially distributed responses. Biometrics 43: 875-883, 1987.
15. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al: Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129: 2220-2232, 2009.
16. Hong WS, Hu DN, Qian GP, et al: Treatment of vitiligo in children and adolescents by autologous cultured pure melanocytes transplantation with comparison of efficacy to results in adults. J Eur Acad Dermatol Venereol 25: 538-543, 2011.
17. Hong WS, Hu DN, Qian GP, et al: Ratio of size of recipient and donor areas in treatment of vitiligo by autologous cultured melanocyte transplantation. Br J Dermatol 165: 520-525, 2011.
18. Yu HS, Chang KL, Yu CL, et al: Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 108: 527-529, 1997.
19. Moretti S, Spallanzani A, Amato L, et al: New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 15: 87-92, 2002.
20. Moretti S, Spallanzani A, Amato L, et al: Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol 138: 273-274, 2002.
21. Tu CX, Gu JS and Lin XR: Increased interleukin-6 and granulocyte- macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 31: 73-78, 2003.
22. Neurath MF and Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer (Review). Cytokine Growth Factor Rev 22: 83-89, 2011.
23. Chalaris A, Garbers C, Rabe B, et al: The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90: 484-494, 2011.
24. Krasagakis K, Hettmannsperger U, Tebbe B and Garbe C: Cutaneous metastatic angiosarcoma with a lethal outcome, following radiotherapy for a cervical carcinoma. Br J Dermatol 133: 610-614, 1995.
25. Krasagakis K, Garbe C, Zouboulis CC and Orfanos CE: Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res 139: 169-182, 1995.
26. Krasagakis K, Garbe C, Eberle J and Orfanos CE: Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch Dermatol Res 287: 259-265, 1995.
27. Kotobuki Y, Tanemura A, Yang L, et al: Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res 25: 219-230, 2012.
28. Dienz O and Rincon M: The effects of IL-6 on CD4 T cell responses (Review). Clin Immunol 130: 27-33, 2009.
29. + T cells. J Exp Med 206: 69-78, 2009.
30. Yoshida H, Hashizume M, Suzuki M and Mihara M: Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol 634: 178-183, 2010.
31. Yoshida H, Hashizume M and Mihara M: IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int 31: 127-131, 2011.
32. Romagnani S, Maggi E, Liotta F, et al: Properties and origin of human Th17 cells (Review). Mol Immunol 47: 3-7, 2009.
33. Suzuki T, Shoji S, Yamamoto K, et al: Essential roles of Lyn in fibronectin-mediated filamentous actin assembly and cell motility in mast cells. J Immunol 161: 3694-3701, 1998.
34. Vercelli D: Genetics of IL-13 and functional relevance of IL-13 variants (Review). Curr Opin Allergy Clin Immunol 2: 389-393, 2002.
35. Mentink-Kane MM and Wynn TA: Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease (Review). Immunol Rev 202: 191-202, 2004.
36. Mentink-Kane MM, Cheever AW, Thompson RW, et al: IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 101: 586-590, 2004.